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370a Tuesday, March 8, 2011(2.3 vs. 1.3 mM1s1) for both S1 and actoS1. The apparent maximum rate
constants of ATP binding to S1 and actoS1 (kmax) are similar for both
a and b (~160 s1 a- & b-S1, ~1400 s1 for a- & b-actoS1). The affinities
of ADP for S1 (a, 2.8; b, 0.5 mM) and for AM (a, 152; b, 21 mM) are much
tighter for b-S1. The ADP dissociation rate constants are also much slower
for b-S1 (2.7 vs. 0.9 s1 for S1 and >1200 vs. 84 s1 for actoS1). The ADP
release rate constant from AMD is of the right order to limit the shortening
velocity of the b isoform. For a-S1 the ADP release is too fast to measure
and faster than kmax of ATP induced dissociation of actoS1 and therefore not
limiting the contraction velocity. The affinity of both S1s for actin is tight (<
30 nM) and ADP weakens this more than 50 fold to 2.4 mM for a-S1 and
less than 5 fold for b-S1. Calculated cycle durations at physiological 5mM
ATP predict that both and spend ~20% of their contractile time actin-
bound, but have greatly different cycle times of ~6 vs. ~84 ms, respectively.
These isoforms are coexpressed in human heart so their diverse kinetics
likely lead to interesting dynamics in their cooperative contributions to car-
diac contraction.
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We used quantitative epi-fluorescence of mant-nucleotides to measure single
nucleotide turnovers in small bundles of permeable rabbit ventricle cells. In
relaxed cells nucleotide turnover occurs in two phases one with a short time
constant, 14 5 1 seconds, and a second with a much longer time constant,
144 5 10 seconds. The first is compatible with the normal relaxed state and
the second arises from myosin heads in the Super Relaxed State (SRX). Ap-
proximately 60% of the myosin heads were in the SRX. Recent work iden-
tified a similar state with a slow nucleotide turnover time constant, 230
seconds, in relaxed vertebrate skeletal muscle (Stewart et.al. PNAS, 2010).
The SRX appears to play a similar role in relaxed skeletal fibers and cardiac
cells providing a state with a very low metabolic rate. However, in active
fibers the properties of the SRX differ dramatically. There is a rapid transi-
tion of myosin heads out of the SRX in active skeletal fibers. In contrast, in
cardiac muscle, the population of myosin heads in the SRX is not changed
when the muscle, is activated. This property allows the SRX to play a very
different role in cardiac cells than in skeletal fibers. The mechanisms that
control cardiac contractility are complex, leading to an output that can
vary from highly active to very quiescent. The ability of myosin heads to
remain in the SRX, while other heads are generating tension, allows this
state to play a role in the regulation of cardiac output. In particular, the super
relaxed state could provide a mechanism for decreasing the metabolic load
on the heart, being cardioprotective, particularly in time of stress such as
ischemia.
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MyBP-C is a potent modulator of cardiac contractility and is localized to
two distinct regions (C-zones) flanking the myosin thick filament (TF)
bare zone. To determine whether MyBP-C modulates actomyosin motion
generation over the entire length of the TF or only within the C-zones,
we isolated native mouse ventricular TFs by mechanical and proteolytic dis-
persion. Negatively-stained EM images showed 1.6mm long TFs with defined
central bare zones. TFs contained intact MyBP-C, confirmed by western
blotting with domain specific antibodies. In a total internal reflectance mi-
croscopy based motility assay, TFs were imaged using fluorescent ATP
and the velocity of fluorescent shards of actin filaments was measured
over the entire length of TFs at 100 mM ATP and 20C. Four distinct veloc-
ities were observed, presumably corresponding to motion toward and away
from the bare zone, over regions with and without MyBP-C, the average ve-
locity of which was similar to that generated by monomeric myosin in the
motility assay (1.050.1mm/s). Limiting our analysis to bare zone directed
motility, actin moved at 1.850.1mm/s starting from the TF end and slowedabruptly to 1.050.1mm/s at 28558nm from the bare zone. In contrast, bare
zone directed motility on TFs from MyBP-C knockout mice demonstrated
only one velocity (1.750.1mm/s), equal to the faster velocity on wildtype
(WT) TFs, suggesting the slow velocity on the WT TFs is due to MyBP-
C. Similarly, only one bare zone directed velocity (1.950.1mm/s) was ob-
served on WT TFs after N-terminal proteolytic truncation of the MyBP-C
with calpain to within the MyBP-C motif (C1-C2 linker). We conclude
that the N-terminal domains of MyBP-C directly modulate actomyosin mo-
tion generation only in a ~285nm region of the thick filament, presumably
the C-zone, where MyBP-C is localized.
1995-Plat
Ablation of Cardiac Myosin Binding Protein-C Accelerates Contractile
Kinetics in the Absence of Hypertrophic Remodeling in Engineered
Cardiac Tissue
Willem J. De Lange, John C. Ralphe.
University of Wisconsin-Madison, Madison, WI, USA.
Truncation mutations in cardiac myosin binding protein-C (cMyBP-C) are
prevalent causes of hypertrophic cardiomyopathy (HCM). Mounting evidence
suggest that truncated cMyBP-C causes HCM through haploinsufficiency.
Mouse models in which cMyBP-C is ablated (KO), or truncated, show varying
degrees of systolic and diastolic dysfunction and alterations in contractile kinet-
ics. Phenotypic variation observed in these models may, however, be related to
secondary adaptations and hypertrophic remodeling, rather than the direct
effect of cMyBP-C depletion.
In order to study the effects of cMyBP-C ablation on contractility in the absence
of hypertrophic remodeling, we produced engineered cardiac tissue (ECT) from
wild type (WT) and (KO) neonatal mouse cardiomyocytes.
Expression levels of several hypertrophic markers were similar in WT and KO
ECT, indicating a lack of hypertrophic remodeling. Contraction (50.051.1ms
vs. 42.951.9ms; p=0.002) and relaxation (41.350.8ms vs. 29.251.7;
p<0.001) times were significantly shorter in KO thanWT ECT. This difference
was more pronounced during relaxation, indicating a possible disconnect in
contraction-relaxation coupling. In order to investigate this possibility, we stud-
ied the 1st order derivative (dFdt) of the force tracings. We found no significant
difference in þdFdMax/-dFdtMax ratios (0.3850.02 vs. 0.4350.03; p=0.178),
indicating that cMyBP-C ablation does not directly affect contraction-
relaxation coupling. Elapsed times between þdFdtMax and peak developed
force (FMax) (27.350.8ms vs. 21.751.5ms; p=0.002), as well as between
FMax and -dFdtMax (36.551.6 vs. 18.452.1ms; p<0.001) was, however, sig-
nificantly shorter.
These findings indicate that cMyBP-C is involved in regulation of contractile
velocity and that its ablation shortens the period of sustained force production.
Our data indicates that previous reports of impaired relaxation and diastolic
dysfunction due to cMyBP-C KO depletion in mice and humans may be caused
by hypertrophic remodeling, rather than directly by cMyBP-C ablation/
haploinsufficiency.
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Function of Cardiac Troponin I
Shirin Akhter, Zhiling Zhang, J.-P. Jin.
Wayne State University, Detroit, MI, USA.
The function of troponin I (TnI) is essential to muscle contraction and heart
function. Three homologous TnI genes are present in vertebrate species en-
coding cardiac, fast and slow skeletal muscle TnI isoforms. In addition to the
core structure conserved in all TnI isoforms, cardiac TnI (cTnI) has an ~30
amino acids NH2-terminal extension. This segment is a regulatory structure
containing the b-adrenergic dependent protein kinase A (PKA) phosphoryla-
tion sites. The NH2-terminal extension of cTnI does not contain binding site
for other troponin subunits and is removable by restricted proteolysis to pro-
vide functional adaptation in stress conditions. The molecular mechanism for
the NH2-terminal modifications to regulate cTnI function is not fully under-
stood. In the present study, we tested a novel hypothesis that the NH2-termi-
nal extension may function through modulating the conformation and
activity of other regions of cTnI. Monoclonal antibody epitope analysis
and protein binding experiments demonstrated that deletion of the NH2-ter-
minal segment altered epitopic conformation in the middle region of cTnI,
similar to the effect of PKA phosphorylation. Such targeted long range con-
formational effect produced changes in the binding affinity for troponin T
and troponin C, with the later in a Ca2þ-dependent manner. These data sug-
gest that the NH2-terminal extension of cTnI regulates cardiac muscle
Tuesday, March 8, 2011 371acontractility through modulating molecular conformation and function of the
core structure of cTnI.
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Heart muscle has been considered to contain predominantly a-Tm (TPM1
gene). However this has not been investigated with tools that can clearly
distinguish all tropomyosin isoforms. We initially used LC/MS to character-
ise the isoforms present in Tm purified from human heart muscle. Mass
spectroscopy of Tm purified from human donor heart showed two dominant
species, a 32754 Da peak, corresponding to acetylated a-Tm and a 32867
Da peak. The second peak was putatively identified by its mass as g-Tm.
These identities were confirmed by comparison with pure recombinant
a and g-skeletal tropomyosin expressed in the baculovirus/sf9 system (sup-
plied by Dr Kristen Nowak, University Western Australia). The novel Tm is
slow-skeletal Tm from the TPM3 gene, also known as g-skeletal tropomy-
osin, (theoretical mass 32859.0 Da). Only very low levels (<5%) of k Tm
or of phosphorylated Tm were detected. Analysis of samples from failing
heart muscle and in myectomy samples showed significantly reduced g-
Tm levels.
The identity of the isoforms characterised in human heart was confirmed by
urea SDS-PAGE, which can separate the two species, and the use of
isoform-specific antibodies. Using the pure recombinant Tms, we demonstrated
that monoclonal antibody CG3 was specific for the g isoform, CH291 was spe-
cific for the a isoform and CH1 did not distinguish between the two isoforms.
Western blotting with these specific antibodies confirmed significant quantities
of g-Tm and a-Tm in both human and mouse hearts. In mice, the level of g-Tm
depends on the strain, being around 50% in many strains, but low in FVB/N
mice.
This discovery is functionally significant as in vitro motility assays using pure
g-Tm and a-Tm shows significant differences between the isoforms.
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Alpha-adrenergic receptor activated protein kinase Ca (PKCa) modifies
cardiac contractile function and is implicated in heart failure. Aim of
the study: To determine the specific effects of PKCa-mediated phosphor-
ylation of cardiac troponin (cTn) on myofilament function in failing cardi-
omyocytes. Methods: Endogenous cTn in Triton-permeabilized
cardiomyocytes from patients with end-stage idiopathic dilated cardiomyop-
athy was partially exchanged (~69%) with PKCa-treated recombinant hu-
man cTn(DD), in which the PKA-sites Ser23/24 on cTnI were mutated
into aspartic acids (D). cTn(DD) was used to rule out in-vitro cross-phos-
phorylation of the PKA-sites by PKCa. A comparison was made between
the effects of PKCa-treated and untreated cTn(DD). Isometric force was
measured at various [Ca2þ] to determine the maximum isometric force
per cross-sectional area (Fmax) and the calcium sensitivity of force
(pCa50). Results: Fmax after exchange with PKCa-treated cTn(DD)
(17.151.9 kN/m2) was significantly reduced in comparison with untreated
cTn(DD) (26.151.9 kN/m2). Subsequent incubation of the cardiomyocytes
with activated PKCa in the PKCa-treated cTn(DD) group did not restore
Fmax. Cardiomyocytes exchanged with PKCa-treated cTn(DD) were moresensitive to Ca2þ (pCa50=5.5950.02) than cells exchanged with untreated
cTn(DD) (pCa50=5.5150.02). Surprisingly, subsequent PKCa-incubation
of cardiomyocytes exchanged with PKCa-treated cTn(DD) caused a reduc-
tion in pCa50 to 5.4550.02. Western blot analysis of PKCa-treated cTn
showed phosphorylation of Ser42 and Thr143 on cTnI. Mass spectrometry
revealed two novel phosphorylation sites: Ser198 on cTnI and Ser179 on
cTnT. Conclusions: Specific in vitro PKCa-mediated phosphorylation of
cTn increases Ca2þ-sensitivity and decreases maximal force. Subsequent
PKCa-mediated phosphorylation of the myofilaments in situ decreases
Ca2þ-sensitivity, without affecting Fmax. These results demonstrate the
dual, site-specific effects of PKCa-mediated phosphorylation in human
myocardium.Platform AV: Protein Conformation
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Protein unfolding, disassembly, and aggregation underlie many diseases, but
detailed study of these processes in intact cells has been limited. Cysteine
Shotgun labeling utilizes cell-permeable fluorescent dyes to label exposed
cysteine residues and was initially applied to study protein structure changes
in response to mechanical stress on cells. We have re-purposed the tech-
nique to identify protein changes in whole-cell lysates in native versus
urea-denaturing conditions and in live cells all as a function of time and
temperature (20-45 deg-C). Labeling rate constants are calculated for any
given Cys site by normalizing the protein labeling kinetics to the rapid la-
beling under denaturing conditions. Proteins can be identified and further
analyzed by mass spectrometry to pinpoint specific, susceptible domains in-
volved. A number of proteins contain cys with a wide variety of rate con-
stants. These proteins include structural proteins such as Filamin A and B,
Talin 1, Myosin 9 and alpha-actinin-4, heat shock protein 1 and elongation
factor 2. Some of these various proteins contain many cysteine-rich domains
and thus appear especially amenable to studying by this new in-cell
technique.
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Fibronectin is an extracellular matrix protein that is assembled by fibroblasts
into fibrils. Previous studies have shown that fibronectin fibrils are extremely
elastic: cells can stretch them up to four times their resting length. The
mechanism of this elasticity has been debated. Some have hypothesized
that unfolding of the 15 Type III domains, each of which are a 7-beta strand
sandwich, drives fibril elasticity. Others have hypothesized that the elasticity
is driven by a conformational change of the entire fibronectin molecule from
a compact to an extended form, without unfolding of Type III domains.
Here we have investigated the unfolding of Type III domains in stretched
fibrils by fluorescent labeling of buried free thiols. We generated a library
of recombinant fibronectins, each of which had a single buried free thiol
in a different Type III domain. Fibronectin matrices containing these re-
combinant fibronectins were labeled with a thiol reactive fluorescent probe;
successful labeling indicated that the domain was unfolded to expose the
buried free thiol, while no labeling suggested that the domain remained
folded. Thiol labeling experiments were also conducted on fibronectin in so-
lution, as some Type III domains have previously been shown to unfold and
refold in the absence of applied tension. Data indicates that Type III do-
mains can be categorized into three groups based on their unfolding proper-
ties: nine (9) Type III domains showed no evidence of unfolding in either
fibrils or solution; four (4) domains showed evidence of unfolding in both
fibrils and in solution; and two (2) domains showed evidence of unfolding
exclusively in fibrils. These results suggest that there is a subset of Type
III domains that unfold within fibronectin that may play a role in fibronectin
fibril elasticity.
